The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

Pfizer

Status and phase: Completed; Phase 2

Conditions: Parkinson's Disease

Treatments: Drug: NR2B NMDA Antagonist CP-101,606 (traxoprodil)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00163085

A1611007

Details and patient eligibility

About

To determine the effects of the NMDA antagonist, CP-101,606, in subjects with Parkinson's Disease

Sex: All

Ages: 30 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 30- 80-year-old PD patients (UK Parkinson's Disease Brain Bank criteria) with a Hoehn & Yahr stage score of 2-5 in the "off" state.

Exclusion criteria

• Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind